What is Frizzle (FRRS1L)?

FRRS1L is a gene in all cells of the brain. Patients with Frizzle (FRRS1L) genetic disease have two non-functioning FRRS1L genes in every brain cell. Non-functioning FRRS1L genes causes the messages in the brain to not get through from one cell to another. These messages affect all areas of function and life for the patient. The resulting disorder produces epilepsy, progressive dyskinesis (abnormal movements), developmental delay, diffuse hypotonia, and global loss of function. Current research shows children having developmental delays, but still gaining abilities, and then between 6-24 months having seizures that cause regression, and rapid loss of function. Frizzle patients are trapped in a body they can’t move, however still retain high cognitive function, understanding, communication, and awareness.

To learn more details about the struggle of children with FRRS1L, please check out the FRRS1L Kids Stories.

Frizzle is a devastating and severely debilitating genetic disease


FRRS1L Gene

  • FRRS1L (Ferric Chelate Reductase 1 Like)

  • FRRS1L gene is a protein coding gene contained in all cells of the brain

  • It helps build key components of the ampa receptor that get produced to sit outside the cell and send messages between cells

  • The loss of function mutations in two FRRS1L genes in a patient causes Frizzle (FRRS1L) genetic disease

  • The FRRS1L gene encodes a protein that is required for assembly of the AMPA subtype of glutamate receptors in the brain

  • The non-functioning genes cause the AMPA-receptors to not be built for the cells, and thus messages are not being sent between the cells in the brain

  • FRRS1L genes are required for AMPA receptor assembly and maturation

  • In the absence of these receptors, there is early onset epilepsy, hyperkinetic movements and developmental delay; followed by severe and rapid regression and loss of function by the age of two years old.

  • FRRS1L is recycled after use


Frizzle (FRRS1L) Genetic Disease
  • FRRS1L (Ferric Chelate Reductase 1 Like) disease = aka Frizzle

  • Also known as early infantile epileptic encephalopathy type 37

  • Patients have two non-functioning FRRS1L genes to have the disease; carriers do not have symptoms

  • Normal pregnancy; at birth there are no medical issues, disease, or deformities with patients’ bodies parts and major body systems

  • Developmental delays

  • Epilepsy and regression onset between 6-24 months of age

  • Rapid regression and loss of motor function; but retain cognitive understanding and awareness

  • Loss of all gross and fine motor skills; loss of oral motor function and airway clearance

  • All patients' wheelchair dependent with head and full body support; G-tube or J-tube fed; requiring 1 to 1,  24/7 skilled care and intervention

  • Seizure control is poor, with epilepsy remaining highly refractory to antiepileptic medications

  • Disease progression and symptoms consistent across patients

  • Secondary health conditions due to loss of function: airway obstructions, respiratory failure, cerebral palsy, hip dysplasia, urology difficulties, infection

  • Threat to life: phenomena, infection, seizures that do not stop


FRRS1L Research

FRRS1L has been found around the world, and in multiple people groups. Currently there are known children in:

  • Afghanistan

  • Bulgaria

  • Croatia

  • Germany

  • India

  • Iran

  • Italy

  • Middle East

  • Netherlands

  • Puerto Rico

  • South Korea

  • Turkey

  • USA

FRRS1L Around the World

Additional Resources

FRRS1L gene disorder presents in children through epilepsy, progressive dyskinesis (abnormal movements), developmental delay, diffuse hypotonia, cortical and cerebellar volume loss, and gradual loss of responsiveness to the environment.

REGISTER

your Frizzle Child/Children

By registering your child/children with Finding Hope for FRRS1L, it provides valuable information that will help us better understand and track the global map of the Frizzle (FRRS1L) community; it will inform researchers; and it also allows us to keep you informed through email updates and news on the progress towards clinical trials for gene replacement therapy. Registering your child is completely optional.